Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. operates as a global diversified pharmaceutical company with business segments spanning gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and eye health. News related to Bausch Health may cover developments across any of these therapeutic areas, including product approvals, clinical trial results, regulatory actions, and commercial launches. The company's Salix business unit focuses on gastroenterology products, with particular emphasis on treatments for hepatic encephalopathy, irritable bowel syndrome, and other gastrointestinal conditions.
Corporate news may include updates on the company's debt management strategies, as Bausch Health has historically carried significant debt obligations stemming from acquisitions. Financial reporting typically addresses performance across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Bausch + Lomb eye health business represents a substantial portion of company operations and may generate independent news flow regarding vision care products, contact lenses, ophthalmic pharmaceuticals, and surgical equipment.
Dermatology news through the Ortho Dermatologics business may cover new acne treatments, psoriasis therapies, and other prescription dermatology products. Aesthetic medicine developments from Solta Medical often involve non-invasive cosmetic treatment technologies. Strategic acquisitions represent a key component of Bausch Health's growth strategy, with the company periodically acquiring businesses with complementary products in core therapeutic areas. Patent litigation and intellectual property matters frequently impact pharmaceutical companies, and Bausch Health may face generic competition for key products as patents expire.
Regulatory filings, including SEC reports, clinical trial registrations, and FDA submissions, provide transparency into company operations and pipeline developments. Investors monitor revenue trends across business segments, particularly the gastroenterology franchise which includes high-value products. Generic pharmaceutical competition, international market performance, and research and development progress all contribute to the ongoing narrative around this diversified pharmaceutical enterprise.
Bausch Health Companies Inc. (NYSE/TSX: BHC) reported on September 14, 2022, the results of its Exchange Offers to exchange existing senior notes valued at up to $4 billion for new secured notes. As of September 13, 2022, holders had tendered approximately $5,577,725,000 in existing notes. The exchange is expected to result in approximately $3,119 million in new secured notes, comprising new first and second lien notes. The Offers will expire on September 27, 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the FDA's tentative approval of Norwich Pharmaceuticals' rifaximin 200 mg product, classified under a Paragraph III filing. The approval will not lead to full authorization until July 24, 2029, when the last of Bausch's patents for XIFAXAN expires. Currently, XIFAXAN contributes less than 1% of Salix's revenues. XIFAXAN is used to treat travelers' diarrhea and has additional indications for major gastrointestinal conditions.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced clarifications regarding its Exchange Offers to exchange existing senior notes for new secured notes. Key points include that Eligible Holders waiving rights related to the exchanged notes and retaining rights under unsold notes. The Offers are exclusively for specific eligible investors, including non-U.S. persons and qualified institutional buyers. All other terms of the Offers remain unchanged. Interested Eligible Holders are encouraged to consult the Exchange Offer Memorandum for full details.
Bausch Health Companies announced the commencement of Exchange Offers to exchange existing senior notes for new secured notes totaling up to $4 billion. The new notes include $2.5 billion in 11% First Lien Secured Notes due 2028 and $500 million in 14% Second Lien Secured Notes due 2030. A support agreement has been signed by holders representing 22.8% of existing notes. The offers will expire on September 27, 2022, with an early tender deadline on September 13, 2022. Investors should assess the details in the Exchange Offer Memorandum.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has transferred approximately 38.6% of its issued shares in Bausch + Lomb Corporation to a wholly-owned unrestricted subsidiary. The Company retains 50.1% of Bausch + Lomb, maintaining an overall 88.7% ownership. This transfer aligns with Bausch Health's plan for the separation of Bausch + Lomb, providing strategic flexibility while evaluating options. The separation is subject to lockup expirations, debt leverage ratios, and necessary approvals.
KBRA has released its latest U.S. Bank Compendium, analyzing the 2Q22 results for U.S. banks rated by KBRA amidst rising interest rates. The report discusses how banks are adjusting to these changes and potential impacts on profitability amid economic uncertainty. Key performance metrics, including credit ratios and returns on assets, are highlighted. The Compendium also provides a quarterly ESG Bulletin featuring Univest Financial Corporation (NASDAQ: UVSP) along with summaries of all publicly traded banks in KBRA's rated universe.
Bausch Health Companies (NYSE/TSX: BHC) announced that the U.S. District Court in Delaware upheld certain patents for XIFAXAN® (rifaximin) 550 mg while invalidating others. The company plans to appeal this decision, with expectations for the appeal to conclude in 12 to 18 months. Currently, Norwich Pharmaceuticals cannot launch a generic version of XIFAXAN until it receives FDA approval for a revised application that excludes the XIFAXAN HE indication. XIFAXAN is indicated for treating IBS-D and preventing hepatic encephalopathy recurrence.
Bausch Health Companies Inc. (BHC) announced support for the new ICD-10 code K76.82 for hepatic encephalopathy (HE), effective October 1, 2022. This code aims to enhance diagnosis and treatment for the rising number of chronic liver disease cases in the U.S., where approximately 4.5 million adults are affected. HE, a complication of cirrhosis, can lead to increased hospitalizations and readmissions. The new code will assist healthcare providers in accurately documenting HE, thereby improving patient care.
Bausch Health Companies Inc. reported second-quarter 2022 revenues of $1.967 billion, down 6% from $2.1 billion in Q2 2021. The decline was attributed to foreign exchange impacts and divestitures. The company's net loss decreased to $145 million compared to $595 million the previous year. Operating income improved significantly to $161 million. Bausch Health is appealing a court decision concerning XIFAXAN patent litigation and is committed to strategic alternatives, including a potential spinoff of Bausch + Lomb, despite ongoing challenges.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to appeal a recent U.S. District Court ruling regarding its XIFAXAN® patents. The court ruled the patents for the treatment of overt hepatic encephalopathy as valid but declared those for irritable bowel syndrome with diarrhea invalid. Bausch intends to challenge this ruling vigorously and prevent Norwich Pharmaceuticals from launching a generic version of XIFAXAN® until at least 2029. The FDA is also revising guidance for rifaximin, which may impact future generic approvals.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
